Meridian Bioscience NAAT for Group A Strep Shines in Multicenter Clinical Study | GenomeWeb

Meridian Bioscience's Illumigene nucleic acid amplification test for Streptococcus pyogenes, or Group A Streptococcus, has a clinical sensitivity of 99 percent and specificity of 99.6 percent when compared to the diagnostic gold standard of culture and discrepant analysis using another nucleic acid amplification test, according to a study published last week in the Journal of Clinical Microbiology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.